| miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis A Gaziel-Sovran, MF Segura, R Di Micco, MK Collins, D Hanniford, ... Cancer cell 20 (1), 104-118, 2011 | 382 | 2011 |
| BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy MF Segura, B Fontanals-Cirera, A Gaziel-Sovran, MV Guijarro, ... Cancer research 73 (20), 6264-6276, 2013 | 246 | 2013 |
| Melanoma MicroRNA signature predicts post-recurrence survival MF Segura, I Belitskaya-Lévy, AE Rose, J Zakrzewski, A Gaziel, ... Clinical cancer research 16 (5), 1577-1586, 2010 | 240 | 2010 |
| Efficient in vivo microRNA targeting of liver metastasis C Huynh, MF Segura, A Gaziel-Sovran, S Menendez, F Darvishian, ... Oncogene 30 (12), 1481-1488, 2011 | 135 | 2011 |
| A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis D Hanniford, J Zhong, L Koetz, A Gaziel-Sovran, DJ Lackaye, S Shang, ... Clinical Cancer Research 21 (21), 4903-4912, 2015 | 80 | 2015 |
| ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1 G Horn, A Gaziel, DH Wreschner, NI Smorodinsky, M Ehrlich Experimental cell research 315 (8), 1490-1504, 2009 | 48 | 2009 |
| Development and characterization of a clinically relevant mouse model of melanoma brain metastasis A Morsi, A Gaziel-Sovran, W Cruz-Munoz, RS Kerbel, JG Golfinos, ... Pigment cell & melanoma research 26 (5), 743, 2013 | 20 | 2013 |
| miRNA-mediated GALNT modulation of invasion and immune suppression: A sweet deal for metastatic cells A Gaziel-Sovran, E Hernando OncoImmunology 1 (5), 3-2, 2012 | 17 | 2012 |
| Krüppel-like factor 4 (KLF4) regulates the miR-183~ 96~ 182 cluster under physiologic and pathologic conditions MF Segura, L Jubierre, SD Li, A Soriano, L Koetz, A Gaziel-Sovran, ... Oncotarget 8 (16), 26298, 2017 | 15 | 2017 |
| In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis A Gaziel-Sovran, I Osman, E Hernando Frontiers in oncology 3, 127, 2013 | 12 | 2013 |
| Compositions and methods for treatment of melanoma E Hernando, M Hoshen, I Osman, A Gaziel-Sovran, MF Segura US Patent 9,421,218, 2016 | 4 | 2016 |
| A microRNA-based signature predicts melanoma brain metastasis at the time of diagnosis D Hanniford, A Gaziel, J Zhong, L Koetz, A Pavlick, RL Shapiro, ... Pigment Cell Melanoma Res 26, 932-1019, 2013 | 4 | 2013 |
| ECOG score as a barrier for clinical trial eligibility in the patient population with genitourinary cancer: Is it time to adapt this criterion to real-world data? L Gortzak Uzan, L Lapidot, T Bader, A Gaziel Journal of Clinical Oncology 41 (6_suppl), 78-78, 2023 | 2 | 2023 |
| In vivo miRNA decoy screen reveals miR-124a as a suppressor of melanoma metastasis RS Moubarak, L Koetz-Ploch, G Mullokandov, A Gaziel, ... Frontiers in Oncology 12, 852952, 2022 | 2 | 2022 |
| Targeting BET proteins in melanoma: A novel treatment approach. L Paoluzzi, MF Segura, B Fontanals-Cirera, A Gaziel-Sovran, MV Guijarro, ... Journal of Clinical Oncology 31 (15_suppl), 9091-9091, 2013 | 2 | 2013 |
| Identification of miRNAs that contribute to melanoma brain metastasis A Gaziel, S Menendez, MF Segura, J Zakrzewski, A Rose, RS Kerbel, ... Cancer Research 70 (8_Supplement), 1946-1946, 2010 | 1 | 2010 |
| Patients with prostate cancer consider clinical trial options significantly earlier in their journey compared to patients with other solid tumors. L Edry-Botzer, Y Lapidot, H Katz, T Bader, A Gaziel Journal of Clinical Oncology 42 (4_suppl), 305-305, 2024 | | 2024 |
| Unveiling disparities in clinical trial participation: Exploring socioeconomic barriers and access to insurance among diverse ethnic groups R Jubran, Y Lapidot, T Bader, A Gaziel CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 32 (12), 2023 | | 2023 |
| Abstract A119: Unveiling disparities in clinical trial participation: Exploring socioeconomic barriers and access to insurance among diverse ethnic groups R Jubran, Y Lapidot, T Bader, A Gaziel Cancer Epidemiology, Biomarkers & Prevention 32 (12_Supplement), A119-A119, 2023 | | 2023 |
| Profound impact of ECOG performance status on clinical trial eligibility and access: Diverging effects by cancer type. Y Lapidot, M Safran, T Bader, A Gaziel JCO Global Oncology 9 (Supplement_1), 97-97, 2023 | | 2023 |
